 "Sun Pharma buys injectables maker Pharmalucence in USA")
To further consolidate its position in the world’s largest pharmaceutical market, Sun Pharmaceutical Industries Ltd has acquired US-based Pharmalucence. According to a statement, Pharmalucence, a sterile injectable capacity in the US, was acquired by one of Sun's US subsidiaries. Pharmalucence, a leading manufacturer of radiopharmaceuticals, has developed a few injectables indicated for cancer treatment.
Pharmalucence is engaged in contract and private label formulation development and manufacturing services of non-cytotoxic human injectables in either liquid or lyophilised form. In mid-2007, Pharmalucence was created via the management buy-out of CIS-US (incorporated in 1985 to commercialise medical applications from isotopic technologies by three long-term employees to become both contract manufacturing organisation (CMO) and a leading manufacturer of radiopharmaceuticals.)
In 2011 and 2012, Pharmalucence received FDA approval for two new indications for its Sulfur Colloid product. Sulfur Colloid is indicated to assist in the localisation of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma.
Pharmalucence is engaged in contract and private label formulation development and manufacturing services of non-cytotoxic human injectables in either liquid or lyophilised form. In mid-2007, Pharmalucence was created via the management buy-out of CIS-US (incorporated in 1985 to commercialise medical applications from isotopic technologies by three long-term employees to become both contract manufacturing organisation (CMO) and a leading manufacturer of radiopharmaceuticals.)
In 2011 and 2012, Pharmalucence received FDA approval for two new indications for its Sulfur Colloid product. Sulfur Colloid is indicated to assist in the localisation of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma.